Key result
C-MIC therapy resulted in similar rates of guideline-directed medical therapy adjustments compared to control over 6 months in patients with non-ischemic HFrEF.
Why the study?
In the C-MIC II trial, C-MIC therapy improved outcomes in patients with HFrEF, but whether differences in background HF medication adjustments influenced these benefits was unknown.
Does C-MIC device therapy alter the need for GDMT and diuretic intensity modifications in ambulatory patients with chronic non-ischemic HFrEF?
RCT (n=65)
Does C-MIC device therapy alter the need for GDMT and diuretic intensity modifications in ambulatory patients with chronic non-ischemic HFrEF?
C-MIC device therapy in non-ischemic HFrEF is associated with a decreased need for HF medication intensification and provides consistent improvements in LVEF and functional status independent of background SGLT2i use.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This is the first randomized trial to demonstrate that low-level microcurrent stimulation can improve both structural heart function and quality of life. It establishes a strong foundation for future studies focused on long-term clinical outcomes.”
“We observed meaningful improvements in symptoms and functional capacity among our patients—an encouraging sign for broader clinical adoption.”
“These results validate more than a decade of translational work. They suggest that restoring myocardial bioelectric signaling can have a direct and clinically meaningful impact on cardiac performance in patients with advanced heart failure.”
No differential GDMT changes explain C-MIC benefits in HFrEF; confirms device effect independent of background therapy optimization.
Background In the C-MIC II trial, C-MIC therapy improved outcomes in patients with heart failure (HF) with reduced ejection fraction (HFrEF). We evaluated whether differences in background HF medication adjustments influenced the observed benefits. Methods Ambulatory patients with chronic non-ischemic HFrEF receiving guideline-directed medical therapy (GDMT) were enrolled. The primary outcome was change in GDMT and diuretic intensity over 6 months. Treatment effects on left ventricular ejection fraction (LVEF), Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), and 6-minute walk distance (6MWD) were assessed by baseline sodium-glucose cotransporter-2 inhibitor (SGLT2i) use for consistency. Results Among 65 patients, 25 (39%) had GDMT adjustments (C-MIC device: 44%; control 33%; p= 0.390). GDMT intensity increased in controls (Δ +0.36) but decreased (Δ -0.16; p= 0.100) in C-MIC group. Diuretic intensity decreased in C-MIC group (Δ -0.10) but increased in controls (Δ +0.12; p= 0.200). When stratified by baseline SGLT2i use, C-MIC therapy induced consistent improvements in LVEF (SGLT2i: +6% [95% CI 3–9; p<0.001] vs. without SGLT2i: +4% [95% CI 2–7; p=0.003]), KCCQ-OSS (SGLT2i: +42 points [95% CI 26–58; p<0.001] vs. without SGLT2i: +40 [95% CI 28–51; p<0.001]) and 6MWD (SGLT2i: +150 meters [95% CI 88–212; p<0.001] vs. without SGLT2i: +141 meters (95% CI 63–219; p<0.001]). Conclusion Medication intensity decreased in C-MIC–treated patients but increased in controls, driven primarily by escalation of diuretics, likely reflecting worsening HF. Consistent improvements in LVEF, 6MWD and KCCQ-OSS across SGLT2i subgroups suggest that the observed benefits are independent of background pharmacologic intensification.
No takes yet. Share an insight, caveat, or question.
Fudim et al. (2026) conducted an RCT in Heart failure with reduced ejection fraction (HFrEF) (n=65). C-MIC therapy vs. Control was evaluated on Change in GDMT and diuretic intensity over 6 months (p=0.390). C-MIC therapy resulted in similar rates of guideline-directed medical therapy adjustments compared to control over 6 months in patients with non-ischemic HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: